Compare Google Inc (GOOG) vs Organon & Co. Common Stock (OGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Google Inc vs Organon & Co. Common Stock — how do they compare? Google Inc trades at $338.36 (market cap $4.30T), while Organon & Co. Common Stock trades at $13.58 (market cap $3.62B). The key difference: Google Inc is far larger — about 1187.8× Organon & Co. Common Stock's market cap, and Organon & Co. Common Stock pays the higher dividend (0.58%). Which is the better fit depends on your goals — on Pluang, investors hold Google Inc for 138 Days and Organon & Co. Common Stock for 0 Days on average.
| GOOG | OGN | |
|---|---|---|
Market Cap | $4.30T | $3.62B |
Volume | 14,394,061 | 2,892,999 |
Sector | Media | Health |
52-Week High | $399.06 | $13.81 |
52-Week Low | $251.34 | $5.70 |
Typical Hold Time | 138 Days | 0 Days |
Enterprise Value | $4.19T | $11.04B |
Dividend Yield | 0.25% | 0.58% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Alphabet (GOOG) trades at $343.65, down 1.52% on the day, with strong technical momentum indicated by bullish moving averages. The company demonstrates robust fundamentals with Q2 2026 EPS of $9.11 beating expectations by 218%, revenue growth accelerating to $402.84B in 2025, and net income margin expanding to 54.77%. Recent news highlights significant AI investments and legal challenges.
Alphabet presents a compelling investment case with strong earnings momentum and dominant market position, though investors face risks from aggressive capital expenditure, potential negative free cash flow, and ongoing securities litigation. The consensus price target of $435.24 suggests 27% upside potential from current levels.
Organon (OGN) trades at $13.77, showing no change in the latest session. The stock demonstrates strong profitability with 52.68% gross margins and 24.04% ROE, though recent quarterly earnings have missed expectations. Valuation appears reasonable with P/E of 17.65 and P/S of 0.59. The company shows positive cash flow trends with 2026 projections indicating $533M net cash flow. Recent FDA developments for MIUDELLA and VTAMA products highlight ongoing pipeline progress.
OGN presents a mixed outlook with solid fundamentals offset by earnings misses. The healthcare company's improving cash flow and product pipeline offer potential upside, but investor sentiment remains divided with analysts showing cautious optimism. Key risks include execution challenges and competitive pressures in the pharmaceutical sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Google Inc
Alphabet Inc. operates as a holding company. The Company, through its subsidiaries, provides web-based search, advertisements, maps, software applications, mobile operating systems, consumer content, enterprise solutions, commerce, and hardware products.
Read more on GOOG →About Organon & Co. Common Stock
Organon & Co. is a global healthcare company focused on women's health, biosimilars, and established brands, spun off from Merck & Co. in 2021. Its portfolio of more than 70 medicines includes contraception and fertility therapies, immunology and oncology biosimilars, and treatments in cardiovascular, respiratory, and dermatology, distributed in over 140 countries.
Read more on OGN →
